Published in N Engl J Med on December 10, 2013
Molecular Disease Profile of Hematological Malignancies (RELab1) | NCT02459743
GENOMED4ALL: Improving MDS Classification and Prognosis by AI | NCT04889729
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood (2013) 3.78
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia (2014) 3.15
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia (2014) 2.28
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood (2014) 2.26
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia (2014) 1.93
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood (2014) 1.79
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood (2015) 1.75
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood (2014) 1.62
Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood (2014) 1.53
JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood (2014) 1.44
Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms. PLoS One (2015) 1.38
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica (2015) 1.32
JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med (2014) 1.31
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature (2014) 1.31
Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis. Leukemia (2013) 1.30
JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov (2015) 1.26
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia (2014) 1.25
Calreticulin mutations in Chinese with primary myelofibrosis. Haematologica (2014) 1.24
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell (2015) 1.24
Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia (2014) 1.20
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun (2015) 1.19
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood (2015) 1.18
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J (2015) 1.15
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica (2014) 1.14
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood (2014) 1.13
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia (2014) 1.12
Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia (2014) 1.11
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood (2014) 1.10
Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. Leukemia (2014) 1.08
Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia (2014) 1.07
Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Leukemia (2014) 1.05
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer (2015) 1.03
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood (2015) 1.03
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia (2015) 1.01
Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling. Leukemia (2014) 1.01
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discov (2016) 1.00
Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res (2014) 0.99
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood (2015) 0.99
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. Haematologica (2014) 0.98
The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica (2016) 0.97
Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms. J Blood Med (2015) 0.97
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A (2014) 0.96
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. J Hematol Oncol (2014) 0.95
Looking for CALR mutations in familial myeloproliferative neoplasms. Leukemia (2014) 0.95
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J (2015) 0.94
Targeting novel signaling pathways for resistant acute myeloid leukemia. Mol Genet Metab (2014) 0.94
Hedgehog signaling in cancer stem cells: a focus on hematological cancers. Stem Cells Cloning (2015) 0.93
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood (2014) 0.93
Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J Exp Med (2014) 0.93
N-Glycan-based ER Molecular Chaperone and Protein Quality Control System: The Calnexin Binding Cycle. Traffic (2016) 0.93
The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. Blood (2014) 0.93
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia (2015) 0.93
Functional roles of calreticulin in cancer biology. Biomed Res Int (2015) 0.93
The intrinsic and extrinsic effects of N-linked glycans on glycoproteostasis. Nat Chem Biol (2014) 0.93
Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling. Nat Med (2015) 0.92
Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis. Haematologica (2015) 0.92
Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. J Hematol Oncol (2014) 0.91
Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients. Haematologica (2014) 0.91
Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. Am J Hematol (2014) 0.90
Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea. Ann Lab Med (2015) 0.90
Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis. Mediators Inflamm (2015) 0.90
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. Cancer Chemother Pharmacol (2016) 0.90
Primary thrombocytosis in children. Haematologica (2014) 0.89
Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis. Blood Cancer J (2015) 0.89
p19 INK4d controls hematopoietic stem cells in a cell-autonomous manner during genotoxic stress and through the microenvironment during aging. Stem Cell Reports (2014) 0.89
MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling. Leukemia (2014) 0.88
CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts. Leukemia (2014) 0.88
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. Onco Targets Ther (2016) 0.88
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med (2015) 0.88
Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica (2015) 0.88
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. J Hematol Oncol (2014) 0.87
High resolution melting analysis: a rapid and accurate method to detect CALR mutations. PLoS One (2014) 0.87
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. Blood Cancer J (2015) 0.87
The importance of calcium in the regulation of megakaryocyte function. Haematologica (2014) 0.87
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia (2015) 0.86
Thrombopoietin receptor is required for the oncogenic function of CALR mutants. Leukemia (2016) 0.86
Calreticulin exon 9 mutations in myeloproliferative neoplasms. Ann Lab Med (2014) 0.85
JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica (2014) 0.85
Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood (2016) 0.84
Targeting a regulator of protein homeostasis in myeloproliferative neoplasms. Nat Med (2016) 0.84
Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation. Mediators Inflamm (2015) 0.84
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis. Haematologica (2016) 0.84
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol (2016) 0.83
The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients. Blood (2015) 0.83
Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation. Bone Marrow Transplant (2016) 0.83
The serum tryptase test: an emerging robust biomarker in clinical hematology. Expert Rev Hematol (2014) 0.83
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol (2016) 0.83
A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies. Leukemia (2015) 0.82
Mutational profile of childhood myeloproliferative neoplasms. Leukemia (2015) 0.82
Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice. Blood (2014) 0.82
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol (2017) 0.82
miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia. Blood Cancer J (2016) 0.82
Angiogenesis in myeloproliferative neoplasms, new markers and future directions. Memo (2014) 0.82
Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms. Mol Cancer (2015) 0.82
AMPylation matches BiP activity to client protein load in the endoplasmic reticulum. Elife (2015) 0.82
Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome. Oncotarget (2015) 0.82
Tissue microarray technique is applicable to bone marrow biopsies of myeloproliferative neoplasms. Histochem Cell Biol (2016) 0.81
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. Haematologica (2014) 0.81
Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant (2014) 0.81
Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature (2002) 45.19
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Proteome survey reveals modularity of the yeast cell machinery. Nature (2006) 20.77
A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature (2007) 18.38
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 10.07
The minimum information required for reporting a molecular interaction experiment (MIMIx). Nat Biotechnol (2007) 8.24
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol (2009) 7.93
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood (2008) 7.73
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol (2007) 7.34
A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol (2004) 7.23
Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat Biotechnol (2010) 7.00
ELM server: A new resource for investigating short functional sites in modular eukaryotic proteins. Nucleic Acids Res (2003) 6.86
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol (2005) 6.06
Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med (2012) 5.87
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Peroxisomes are signaling platforms for antiviral innate immunity. Cell (2010) 5.24
Paternally induced transgenerational environmental reprogramming of metabolic gene expression in mammals. Cell (2010) 5.22
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16
Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet (2011) 4.85
Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med (2004) 4.66
Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry (2008) 4.65
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood (2011) 4.43
The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat Methods (2013) 4.34
Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution. Nat Methods (2010) 4.30
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nat Protoc (2011) 4.18
IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nat Immunol (2011) 4.18
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood (2013) 3.78
Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75
Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med (2008) 3.69
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59
The Swedish Twin Registry in the third millennium: an update. Twin Res Hum Genet (2006) 3.58
A myristoyl/phosphotyrosine switch regulates c-Abl. Cell (2003) 3.48
An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nat Methods (2006) 3.38
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med (2004) 3.26
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
Target profiling of small molecules by chemical proteomics. Nat Chem Biol (2009) 3.20
High-throughput bisulfite sequencing in mammalian genomes. Methods (2009) 3.14
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica (2011) 3.11
Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol (2004) 3.10
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet (2009) 3.00
Genomic distribution and inter-sample variation of non-CpG methylation across human cell types. PLoS Genet (2011) 2.98
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med (2005) 2.94
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica (2008) 2.92
Structure-based assembly of protein complexes in yeast. Science (2004) 2.89
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood (2014) 2.72
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica (2008) 2.69
Genome-wide analysis of Notch signalling in Drosophila by transgenic RNAi. Nature (2009) 2.68
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood (2004) 2.64
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol (2013) 2.63
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood (2013) 2.60
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol (2010) 2.53
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A (2007) 2.51
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol (2005) 2.50
Sequential ChIP-bisulfite sequencing enables direct genome-scale investigation of chromatin and DNA methylation cross-talk. Genome Res (2012) 2.49
LUMA (LUminometric Methylation Assay)--a high throughput method to the analysis of genomic DNA methylation. Exp Cell Res (2006) 2.48
Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell (2008) 2.46
Rediscovering the sweet spot in drug discovery. Drug Discov Today (2003) 2.45
Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int (2005) 2.42
Erosion of dosage compensation impacts human iPSC disease modeling. Cell Stem Cell (2012) 2.42
RNA chaperones, RNA annealers and RNA helicases. RNA Biol (2007) 2.41
NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol (2009) 2.39
DNA methylation analysis of chromosome 21 gene promoters at single base pair and single allele resolution. PLoS Genet (2009) 2.37
Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn (2007) 2.35
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood (2012) 2.32